ArticleCurrent microbiology2026
Thymoquinone from Lichen Dirinaria frostii (Tuck.): A New Promising Antimicrobial Compound.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The present study reports the presence of thymoquinone (TQ), a promising benzoquinone compound, in the lichen Dirinaria frostii (strain DF_MSCBU, NCBI-accession no. PP955960), collected from Similipal National Park, India. The extract of D. frostii was subjected to GCMS analysis and detected the presence of thymoquinone. Further, purification of the TQ fraction was carried out using HPLC against a standard thymoquinone reference. FTIR analysis identified the key functional groups. In addition, Nuclear Magnetic Resonance (¹H NMR and ¹³C NMR) spectroscopy was performed to determine the structure and composition of the molecule. The purified TQ was then used for antibacterial assays against pathogenic bacteria Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Vibrio cholerae following the MIC method showed pathogen inhibition at different incubation time, of both Gram +ve and Gram -ve bacteria. Thymoquinone showed significant bactericidal activity compared to the standard antibiotics azithromycin, streptomycin, and erythromycin in a dose-dependent manner. This study demonstrates occurrence of thymoquinone from D. frostii as a novel finding and opens new possibilities for its therapeutic applications in the future.
Indexed as
Identifiers
41653215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.